IL106665A - Powder compositions for inhalation and process for their preparation - Google Patents
Powder compositions for inhalation and process for their preparationInfo
- Publication number
- IL106665A IL106665A IL106665A IL10666593A IL106665A IL 106665 A IL106665 A IL 106665A IL 106665 A IL106665 A IL 106665A IL 10666593 A IL10666593 A IL 10666593A IL 106665 A IL106665 A IL 106665A
- Authority
- IL
- Israel
- Prior art keywords
- weight
- composition according
- carrier
- microns
- drug
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 102
- 239000000843 powder Substances 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 title claims description 7
- 239000003814 drug Substances 0.000 claims abstract description 40
- 229940079593 drug Drugs 0.000 claims abstract description 33
- 239000002216 antistatic agent Substances 0.000 claims abstract description 24
- 239000002245 particle Substances 0.000 claims description 31
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 238000009826 distribution Methods 0.000 claims description 13
- 239000008101 lactose Substances 0.000 claims description 13
- -1 sorbitan fatty acid ester Chemical class 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 9
- 239000000654 additive Substances 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 150000003936 benzamides Chemical class 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229960004436 budesonide Drugs 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 229940112141 dry powder inhaler Drugs 0.000 claims description 2
- 229960001022 fenoterol Drugs 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 108060001064 Calcitonin Proteins 0.000 claims 1
- IROWCYIEJAOFOW-UHFFFAOYSA-N DL-Isoprenaline hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 IROWCYIEJAOFOW-UHFFFAOYSA-N 0.000 claims 1
- 239000001836 Dioctyl sodium sulphosuccinate Substances 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 239000004147 Sorbitan trioleate Substances 0.000 claims 1
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 1
- 229960004015 calcitonin Drugs 0.000 claims 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims 1
- 235000019337 sorbitan trioleate Nutrition 0.000 claims 1
- 229960000391 sorbitan trioleate Drugs 0.000 claims 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 16
- 238000011049 filling Methods 0.000 description 14
- 210000004072 lung Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 229910021653 sulphate ion Inorganic materials 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000005429 filling process Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 238000012369 In process control Methods 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010038731 Respiratory tract irritation Diseases 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- ZBNRGEMZNWHCGA-PDKVEDEMSA-N [(2r)-2-[(2r,3r,4s)-3,4-bis[[(z)-octadec-9-enoyl]oxy]oxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC ZBNRGEMZNWHCGA-PDKVEDEMSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000005239 aroylamino group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010965 in-process control Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000000420 mucociliary effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008249 pharmaceutical aerosol Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Otolaryngology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9217312A GB2269992A (en) | 1992-08-14 | 1992-08-14 | Powder inhalation formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL106665A0 IL106665A0 (en) | 1993-12-08 |
| IL106665A true IL106665A (en) | 1998-02-22 |
Family
ID=10720370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL106665A IL106665A (en) | 1992-08-14 | 1993-08-12 | Powder compositions for inhalation and process for their preparation |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5908639A (de) |
| EP (1) | EP0654991B1 (de) |
| JP (1) | JP3787573B2 (de) |
| AT (1) | ATE154237T1 (de) |
| AU (1) | AU678379B2 (de) |
| CA (1) | CA2142126C (de) |
| DE (1) | DE69311556T2 (de) |
| DK (1) | DK0654991T3 (de) |
| ES (1) | ES2106362T3 (de) |
| GB (1) | GB2269992A (de) |
| GR (1) | GR3024468T3 (de) |
| IL (1) | IL106665A (de) |
| MX (1) | MX9304975A (de) |
| NZ (1) | NZ254945A (de) |
| WO (1) | WO1994004133A1 (de) |
| ZA (1) | ZA935943B (de) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9322014D0 (en) | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| US5612053A (en) | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
| GB9515182D0 (en) | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
| US6017963A (en) * | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
| US20020052310A1 (en) | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5871010A (en) * | 1996-06-10 | 1999-02-16 | Sarnoff Corporation | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
| FR2756739B1 (fr) * | 1996-12-05 | 2000-04-28 | Astra Ab | Nouvelle formulation de budesonide |
| SE9700133D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| JP2001514663A (ja) | 1997-03-12 | 2001-09-11 | エスモンド，ロバート ダブリュー． | アルツハイマー病を処置または予防するための方法 |
| US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6565885B1 (en) * | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| US6956021B1 (en) | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
| US6191154B1 (en) | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| JP4691298B2 (ja) * | 1999-10-12 | 2011-06-01 | 科研製薬株式会社 | 粉末吸入用製剤及びその製造方法 |
| ES2343124T3 (es) | 1999-10-29 | 2010-07-23 | Novartis Ag | Composiciones de polvo seco con dispersabilidad mejorada. |
| WO2001056581A1 (en) * | 2000-02-04 | 2001-08-09 | Kissei Pharmaceutical Co., Ltd. | Powdered preparation for inhalation and powder inhalant containing the same packed |
| EP1261316B1 (de) | 2000-02-28 | 2008-04-23 | PharmaKodex Limited | Verabreichungssystemen für oral anzuwendende arzneimittel |
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| EP2266549B1 (de) * | 2000-06-27 | 2019-08-07 | Vectura Limited | Verfahren zur Herstellung von Partikeln zur Verwendung in einer pharmazeutischen Zusammensetzung |
| JP5698423B2 (ja) * | 2000-06-27 | 2015-04-08 | ベクトゥラ・リミテッド | 医薬組成物で使用するための粒子の製造法 |
| AU2002220857A1 (en) * | 2000-11-30 | 2002-06-11 | Vectura Limited | Particles for use in a pharmaceutical composition |
| EP2283817B1 (de) | 2000-11-30 | 2016-05-18 | Vectura Limited | Herstellungsverfahren für Partikel zur Verwendung in einer Arrzneizusammensetzung |
| CA2433335C (en) | 2000-12-29 | 2010-04-20 | Advanced Inhalation Research, Inc. | Particles for inhalation having sustained release properties |
| WO2003020197A1 (en) | 2001-09-05 | 2003-03-13 | Vectura Limited | Improvements in or relating to the delivery of oral drugs |
| US7182961B2 (en) | 2001-11-20 | 2007-02-27 | Advanced Inhalation Research, Inc. | Particulate compositions for pulmonary delivery |
| ATE508735T1 (de) | 2001-12-19 | 2011-05-15 | Novartis Ag | Pulmonale verabreichung von aminoglykosiden |
| AU2003209475A1 (en) | 2002-03-07 | 2003-09-16 | Vectura Limited | Fast melt multiparticulate formulations for oral delivery |
| SI1494732T1 (sl) | 2002-03-20 | 2008-08-31 | Mannking Corp | Inhalacijski aparat |
| WO2004073729A1 (ja) | 2003-02-21 | 2004-09-02 | Translational Research Ltd. | 薬物の経鼻投与用組成物 |
| MXPA05010379A (es) | 2003-03-27 | 2006-05-31 | Bioactis Ltd | Aparato para administrar una medicina en polvo en la cavidad intranasal. |
| ITMI20040795A1 (it) * | 2004-04-23 | 2004-07-23 | Eratech S R L | Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa |
| US8673360B2 (en) | 2004-08-10 | 2014-03-18 | Shin Nippon Biomedical Laboratories, Ltd. | Compositions that enable rapid-acting and highly absorptive intranasal administration |
| AU2005277208B2 (en) | 2004-08-20 | 2011-11-24 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
| DK1791542T3 (en) | 2004-08-23 | 2015-06-15 | Mannkind Corp | Diketopiperazinsalte for pharmaceutical delivery |
| EP1657278A1 (de) | 2004-11-12 | 2006-05-17 | SOLVAY (Société Anonyme) | Beschichtete Calciumcarbonat-Teilchen mit grosser spezifischer Oberfläche |
| KR101486397B1 (ko) | 2005-09-14 | 2015-01-28 | 맨카인드 코포레이션 | 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법 |
| US20070172430A1 (en) * | 2006-01-20 | 2007-07-26 | Nastech Pharmaceutical Company Inc. | Dry powder compositions for rna influenza therapeutics |
| AU2007216966C1 (en) | 2006-02-22 | 2014-03-20 | Mannkind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
| WO2008078730A1 (ja) | 2006-12-26 | 2008-07-03 | Translational Research, Ltd. | 経鼻投与用製剤 |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| CN109568740B (zh) | 2008-06-13 | 2022-05-27 | 曼金德公司 | 干粉吸入器和用于药物输送的系统 |
| BRPI0914308B8 (pt) | 2008-06-20 | 2021-06-22 | Mannkind Corp | sistema de inalação |
| JP5936353B2 (ja) * | 2008-07-18 | 2016-06-22 | プロソニックス リミテッドＰｒｏｓｏｎｉｘ Ｌｉｍｉｔｅｄ | フルチカゾン粒子の結晶化度を改善する方法 |
| TWI532497B (zh) | 2008-08-11 | 2016-05-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| EP4578502A3 (de) | 2009-02-26 | 2025-10-08 | Glaxo Group Limited | Pharmazeutische formulierungen enthaltend 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
| EP2405963B1 (de) | 2009-03-11 | 2013-11-06 | MannKind Corporation | Gerät, system und verfahren zur messung von widerstand in einem inhaliergerät |
| EP2429495A4 (de) | 2009-05-15 | 2014-01-22 | Shin Nippon Biomedical Lab Ltd | Intranasale pharmazeutische zusammensetzung mit verbesserter pharmakokinetik |
| MY186975A (en) | 2009-06-12 | 2021-08-26 | Mannkind Corp | Diketopiperazine microparticles with defined specific surface areas |
| WO2011013003A2 (en) | 2009-07-31 | 2011-02-03 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal granisetron and nasal applicator |
| EP2496295A1 (de) | 2009-11-03 | 2012-09-12 | MannKind Corporation | Vorrichtung und verfahren zur simulation von einatmungsanstrengungen |
| GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| IL223742A (en) | 2010-06-21 | 2016-06-30 | Mannkind Corp | A dry powder inhaler and preparation for it |
| DK2694402T3 (en) | 2011-04-01 | 2017-07-03 | Mannkind Corp | BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| HK1201475A1 (en) | 2011-10-24 | 2015-09-04 | Mannkind Corporation | Methods and compositions for treating pain |
| SG11201500218VA (en) | 2012-07-12 | 2015-03-30 | Mannkind Corp | Dry powder drug delivery systems and methods |
| EP2911690A1 (de) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalierbare influenza-impfstoffzusammensetzungen und verfahren |
| ES2754388T3 (es) | 2013-03-15 | 2020-04-17 | Mannkind Corp | Composiciones y métodos de dicetopiperazina microcristalina |
| EP3021834A1 (de) | 2013-07-18 | 2016-05-25 | MannKind Corporation | Hitzestabile pharmazeutische trockenpulverzusammensetzungen und verfahren |
| JP2016530930A (ja) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | 通気装置及び方法 |
| WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| US11744967B2 (en) | 2017-09-26 | 2023-09-05 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal delivery devices |
| WO2021242808A1 (en) | 2020-05-26 | 2021-12-02 | Rhodes Technologies | Cannabinoid compositions and dosage forms for intranasal or inhalational delivery |
| JP7606825B2 (ja) * | 2020-06-15 | 2024-12-26 | 東和薬品株式会社 | エソメプラゾール顆粒ならびにその製造方法および用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4581225A (en) * | 1984-04-25 | 1986-04-08 | Eli Lilly And Company | Sustained release intranasal formulation and method of use thereof |
| US4916230A (en) * | 1984-07-02 | 1990-04-10 | Merck & Co., Inc. | Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs |
| DE3872635T2 (de) * | 1987-04-09 | 1992-12-17 | Fisons Plc | Pentamidin enthaltende pharmazeutische zusammensetzungen. |
| US5039699A (en) * | 1989-03-27 | 1991-08-13 | Lederle (Japan), Ltd. | Anti-peptic ulcer agent |
| JPH05963A (ja) * | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| GB9020544D0 (en) * | 1990-09-20 | 1990-10-31 | Sandoz Ltd | Improvements in or relating to organic compounds |
| IE71647B1 (en) * | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
-
1992
- 1992-08-14 GB GB9217312A patent/GB2269992A/en not_active Withdrawn
-
1993
- 1993-08-12 IL IL106665A patent/IL106665A/en not_active IP Right Cessation
- 1993-08-13 NZ NZ254945A patent/NZ254945A/en not_active IP Right Cessation
- 1993-08-13 AT AT93918018T patent/ATE154237T1/de active
- 1993-08-13 AU AU47256/93A patent/AU678379B2/en not_active Expired
- 1993-08-13 ES ES93918018T patent/ES2106362T3/es not_active Expired - Lifetime
- 1993-08-13 CA CA002142126A patent/CA2142126C/en not_active Expired - Lifetime
- 1993-08-13 EP EP93918018A patent/EP0654991B1/de not_active Expired - Lifetime
- 1993-08-13 DE DE69311556T patent/DE69311556T2/de not_active Expired - Lifetime
- 1993-08-13 WO PCT/GB1993/001720 patent/WO1994004133A1/en not_active Ceased
- 1993-08-13 ZA ZA935943A patent/ZA935943B/xx unknown
- 1993-08-13 DK DK93918018.8T patent/DK0654991T3/da active
- 1993-08-13 JP JP50601794A patent/JP3787573B2/ja not_active Expired - Fee Related
- 1993-08-16 MX MX9304975A patent/MX9304975A/es unknown
-
1997
- 1997-03-19 US US08/821,702 patent/US5908639A/en not_active Expired - Lifetime
- 1997-08-14 GR GR970402106T patent/GR3024468T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ254945A (en) | 1996-06-25 |
| EP0654991B1 (de) | 1997-06-11 |
| JPH08500109A (ja) | 1996-01-09 |
| MX9304975A (es) | 1994-05-31 |
| JP3787573B2 (ja) | 2006-06-21 |
| ES2106362T3 (es) | 1997-11-01 |
| ZA935943B (en) | 1994-06-09 |
| EP0654991A1 (de) | 1995-05-31 |
| AU678379B2 (en) | 1997-05-29 |
| DK0654991T3 (da) | 1997-12-29 |
| CA2142126A1 (en) | 1994-03-03 |
| ATE154237T1 (de) | 1997-06-15 |
| GB2269992A (en) | 1994-03-02 |
| GR3024468T3 (en) | 1997-11-28 |
| DE69311556T2 (de) | 1997-12-04 |
| WO1994004133A1 (en) | 1994-03-03 |
| US5908639A (en) | 1999-06-01 |
| CA2142126C (en) | 2007-01-09 |
| AU4725693A (en) | 1994-03-15 |
| GB9217312D0 (en) | 1992-09-30 |
| IL106665A0 (en) | 1993-12-08 |
| DE69311556D1 (de) | 1997-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0654991B1 (de) | Inhalationspulver enthaltend antistatisches hilfsmittel | |
| EP0731688B1 (de) | Aerosole als darreichungsform mit cfc-freiem treibmittel | |
| US6372246B1 (en) | Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals | |
| US20070253913A1 (en) | Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation | |
| JP2007513152A (ja) | 耐湿性容器内のチオトロピウムから構成される医薬製品 | |
| AU2003218306B2 (en) | Method for administration of growth hormone via pulmonary delivery | |
| HUP0101608A2 (hu) | Aeroszol formájú gyógyszerkészítmény és eljárás előállítására | |
| NZ246047A (en) | Powder for inhalation comprising a micronised active ingredient and an excipient which has particles of 20um or more and finer particles of 10 um or less | |
| PL207377B1 (pl) | Medyczny preparat aerozolowy, sposób wytwarzania medycznego preparatu aerozolowego oraz zastosowanie soli kwasów karboksylowych jako środków pomocniczych w tym preparacie | |
| JPS6313965B2 (de) | ||
| HK1200343A1 (en) | An inhalable medicament comprising tiotropium | |
| US20210154137A1 (en) | Dry powder vancomycin compositions and associated methods | |
| AU2003269989B2 (en) | Inhalation composition | |
| US20020155068A1 (en) | Inhalatory compositions of formoterol | |
| CA2499280A1 (en) | Inhalation compositions with high drug ratios | |
| EP2957553A1 (de) | Pharmazeutische formulierungen von vilanterol | |
| EP2957552B1 (de) | Vilanterolformulierungen | |
| CA2360649C (en) | Method of preparing particles for agglomeration | |
| JP2025526811A (ja) | 吸入可能なエピネフリン製剤 | |
| EP2957551B1 (de) | Trockenpulverformulierungen mit vilanterol | |
| JP2004523536A5 (de) | ||
| GB1333767A (en) | Pharmaceutical compositions for inhalation comprising n-isopropyl noratropinium methylate salts | |
| EA003193B1 (ru) | Микронизированные фармацевтические композиции | |
| US20050163725A1 (en) | Method for administration of growth hormone via pulmonary delivery | |
| EP2957550A1 (de) | Pharmazeutische formulierungen mit vilanterol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |